BioMedNewsBreaks — Regentis Biomaterials Ltd.’s (NYSE American: RGNT) GelrinC Advances Toward New Era of Regenerative Orthopedic Care

Regentis Biomaterials (NYSE American: RGNT) is advancing a regenerative approach to cartilage repair with GelrinC, a cell-free, off-the-shelf hydrogel implant designed to create a temporary environment that supports the body’s natural ability to regenerate damaged knee cartilage. Unlike conventional implants that primarily replace or reinforce damaged tissue, GelrinC is injected into a cartilage lesion and cured in place with ultraviolet light before gradually degrading as new tissue develops. The company reports encouraging clinical results, including greater pain improvement versus microfracture at two years and MRI evidence of cartilage regeneration. GelrinC already has CE Mark approval in Europe, where Regentis is preparing for commercialization, while its U.S. pivotal Phase III SAGE study has surpassed 50% enrollment. Regentis has also reported a new manufacturing process capable of improving production yield by 400%, potentially supporting future scalability as the company works to advance GelrinC toward a possible FDA approval and broader adoption of regenerative orthopedic care.

To view the full article, visit https://ibn.fm/hf5jQ

About Regentis Biomaterials Ltd.

Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R) is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT